Blog Anti-Diabetes Therapies and Bone Safety May 28, 2013 Recent information indicates that 50% of elderly individuals in the US are osteoporotic and almost 20% of the population is either diabetic or prediabetic. Type 2 Diabetes Treatments and Potential Effects on Bone May 21, 2013 This post will focus on the currently available treatments for Diabetes along with new therapeutic targets and their potential for effects on bone. Diabetes and the Skeleton: A Sweeter Look to the Future May 13, 2013 Chronic hyperglycemia due to either insulin deficiency or insulin resistance is associated with multiple end organ complications. Less often recognized is the long term effect of high glucose on the skeleton. Mission at Work: Mike Hession Feb 15, 2013 Inspiring stories profiling how Charles River employees and their families are benefiting from our work. Animal Models of Obesity: A Crash Course Jan 14, 2013 Studying obesity with animal models? Research Models Specialist, Alice McVey, gives advice to obesity researchers looking for the appropriate animal model. Immunometabolism: The Crossroads between Diabetes and Inflammation Jan 08, 2013 Two of the most fundamental requirements to our survival are the ability to survive periods of starvation and the capacity to mount an effective response against pathogenic invaders. NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines? Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise. Displaying results 1-10 (of 25) |< < 1 - 2 - 3 > >|
Anti-Diabetes Therapies and Bone Safety May 28, 2013 Recent information indicates that 50% of elderly individuals in the US are osteoporotic and almost 20% of the population is either diabetic or prediabetic.
Type 2 Diabetes Treatments and Potential Effects on Bone May 21, 2013 This post will focus on the currently available treatments for Diabetes along with new therapeutic targets and their potential for effects on bone.
Diabetes and the Skeleton: A Sweeter Look to the Future May 13, 2013 Chronic hyperglycemia due to either insulin deficiency or insulin resistance is associated with multiple end organ complications. Less often recognized is the long term effect of high glucose on the skeleton.
Mission at Work: Mike Hession Feb 15, 2013 Inspiring stories profiling how Charles River employees and their families are benefiting from our work.
Animal Models of Obesity: A Crash Course Jan 14, 2013 Studying obesity with animal models? Research Models Specialist, Alice McVey, gives advice to obesity researchers looking for the appropriate animal model.
Immunometabolism: The Crossroads between Diabetes and Inflammation Jan 08, 2013 Two of the most fundamental requirements to our survival are the ability to survive periods of starvation and the capacity to mount an effective response against pathogenic invaders.
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
Abandon the Amyloid Hypothesis? New Research Says Not So Fast Nov 26, 2012 After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise.
